Methylphenidate Humantis: Uses, Dosage & Side Effects
A modified-release methylphenidate capsule for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults
Methylphenidate Humantis is a prescription central nervous system (CNS) stimulant containing methylphenidate hydrochloride in a modified-release capsule formulation. It is used to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents, and adults as part of a comprehensive treatment program. The modified-release formulation provides an initial rapid onset of action followed by sustained drug delivery throughout the day, reducing the need for multiple daily doses. Methylphenidate works by increasing the levels of dopamine and norepinephrine in the brain, improving attention, focus, and impulse control. It is one of the most widely studied and prescribed medications for ADHD worldwide, and is included on the WHO Model List of Essential Medicines.
Quick Facts: Methylphenidate Humantis
Key Takeaways
- Methylphenidate Humantis is a modified-release capsule containing methylphenidate hydrochloride, used to treat ADHD in children (6+), adolescents, and adults as part of a comprehensive treatment plan including psychological and educational support.
- The modified-release formulation provides biphasic drug delivery – a rapid initial release for quick symptom control followed by gradual extended release for all-day coverage, typically eliminating the need for a midday dose.
- Common side effects include decreased appetite, insomnia, headache, and mild cardiovascular effects (increased heart rate, blood pressure); most are dose-dependent and manageable with dose adjustment.
- Methylphenidate is a controlled substance with abuse potential, but when used as prescribed for ADHD, the risk of dependence is low and research suggests it may actually reduce the risk of later substance use disorders.
- Regular monitoring of height, weight, blood pressure, heart rate, and psychiatric symptoms is recommended, and treatment should be periodically reassessed to determine whether continued medication is necessary.
What Is Methylphenidate Humantis and What Is It Used For?
Methylphenidate Humantis contains the active substance methylphenidate hydrochloride, a piperidine derivative that belongs to the class of central nervous system (CNS) stimulants. Methylphenidate has been used in clinical practice since the 1950s and is one of the most extensively studied psychotropic medications in all of medicine. It is recognized by the World Health Organization (WHO) as an essential medicine and is the first-line pharmacological treatment for ADHD recommended by major international guidelines, including those from the National Institute for Health and Care Excellence (NICE), the European Network for Hyperkinetic Disorders (EUNETHYDIS), and the American Academy of Pediatrics (AAP).
ADHD is a neurodevelopmental disorder characterized by a persistent pattern of inattention, hyperactivity, and impulsivity that interferes with functioning or development. It affects approximately 5–7% of children and adolescents worldwide, and symptoms persist into adulthood in approximately 60–70% of cases, with an estimated adult prevalence of 2.5–4%. The disorder has a strong genetic component, with heritability estimated at 70–80%, and is associated with dysregulation of dopaminergic and noradrenergic neurotransmitter systems, particularly in the prefrontal cortex and striatum. These brain regions are critical for executive functions such as sustained attention, working memory, planning, impulse inhibition, and behavioral regulation.
Methylphenidate exerts its therapeutic effects primarily by blocking the dopamine transporter (DAT) and norepinephrine transporter (NET) on presynaptic neurons. By inhibiting the reuptake of these neurotransmitters, methylphenidate increases their concentration in the synaptic cleft, thereby enhancing dopaminergic and noradrenergic signaling in underactive brain circuits. Positron emission tomography (PET) studies have shown that therapeutic doses of oral methylphenidate occupy approximately 50–75% of striatal DAT, which is sufficient to produce clinically meaningful increases in extracellular dopamine without the euphoric effects associated with higher levels of transporter blockade seen with substances of abuse.
The modified-release capsule formulation of Methylphenidate Humantis is designed to provide a biphasic release profile. The capsule contains both immediate-release and extended-release beads. Upon ingestion, the immediate-release component dissolves rapidly and provides a quick onset of action, typically within 30–60 minutes. The extended-release component is coated with a pH-dependent polymer that dissolves more gradually, providing a second wave of drug release several hours later. This biphasic delivery mimics the effect of taking two separate immediate-release doses, but in a single daily capsule, providing symptom coverage for approximately 8–12 hours depending on the individual patient.
Methylphenidate Humantis is indicated for the treatment of ADHD in children aged 6 years and older, adolescents, and adults. The diagnosis of ADHD must be established according to current diagnostic criteria (DSM-5 or ICD-11) and should be based on a comprehensive clinical assessment. Treatment with methylphenidate should be initiated under the supervision of a specialist in behavioral disorders of childhood and adolescence (or a psychiatrist for adults) and is intended as part of a multimodal treatment approach that typically includes psychological interventions (such as cognitive behavioral therapy), educational accommodations, and family support strategies. Methylphenidate alone is not recommended as the sole treatment component.
Methylphenidate Humantis should be used as part of a comprehensive treatment program for ADHD. This means it should be combined with psychological, educational, and social measures tailored to the individual patient. Medication alone is not sufficient – the best outcomes are achieved when pharmacotherapy is combined with behavioral interventions, skills training, and environmental modifications. Your doctor will periodically evaluate whether continued medication is necessary.
What Should You Know Before Taking Methylphenidate Humantis?
Before prescribing Methylphenidate Humantis, your doctor will conduct a thorough medical evaluation to ensure the medication is safe and appropriate for you. This evaluation typically includes a complete medical history, physical examination, assessment of cardiovascular status (including blood pressure, heart rate, and family history of cardiac disease), psychiatric screening, and evaluation of growth parameters in children and adolescents. Understanding the contraindications, warnings, and precautions associated with methylphenidate is essential for safe use.
Contraindications
Methylphenidate Humantis must not be used in the following situations:
- Hypersensitivity: Known allergy to methylphenidate hydrochloride or any of the excipients in the formulation.
- Glaucoma: Methylphenidate can increase intraocular pressure and is contraindicated in patients with angle-closure glaucoma.
- Pheochromocytoma: The sympathomimetic effects of methylphenidate may precipitate a hypertensive crisis in patients with catecholamine-secreting tumors.
- Hyperthyroidism or thyrotoxicosis: Methylphenidate may worsen symptoms of excess thyroid hormone activity.
- Severe cardiovascular disorders: Including severe hypertension, heart failure, hemodynamically significant congenital heart disease, cardiomyopathies, recent myocardial infarction, life-threatening arrhythmias, and channelopathies (disorders caused by dysfunctional ion channels).
- MAO inhibitor use: Concurrent use with monoamine oxidase (MAO) inhibitors, or within 14 days of discontinuing an MAO inhibitor, due to the risk of hypertensive crisis.
- Severe depression, anorexia nervosa, suicidal tendencies, or psychotic symptoms: Methylphenidate may worsen these conditions.
- Cerebrovascular disorders: Including cerebral aneurysm, vascular abnormalities including vasculitis, or history of stroke.
Warnings and Precautions
Several important warnings and precautions apply to the use of Methylphenidate Humantis. Patients and caregivers should be aware of the following:
Cardiovascular monitoring: Methylphenidate causes modest increases in heart rate (typically 3–6 beats per minute) and blood pressure (typically 2–4 mmHg systolic and 1–3 mmHg diastolic). While these changes are clinically insignificant for most patients, they may be meaningful in individuals with pre-existing cardiovascular conditions. Blood pressure and heart rate should be recorded on a centile chart at each dose adjustment and then at least every 6 months. A thorough cardiac history should be obtained before starting treatment, including family history of sudden cardiac death or unexplained death in young people. An ECG may be considered at baseline in patients with risk factors.
Psychiatric monitoring: Methylphenidate may unmask or exacerbate pre-existing psychiatric conditions, including anxiety, agitation, psychosis, mania, aggression, and tic disorders. New psychotic or manic symptoms appearing during treatment should prompt consideration of a causal relationship with methylphenidate. Patients with comorbid bipolar disorder should be treated with particular caution, as stimulants may precipitate manic episodes. Suicidal ideation should be monitored, particularly during the initial months of treatment and after dose changes.
Growth monitoring: Long-term use of methylphenidate has been associated with modest reductions in growth velocity (height and weight) in children. On average, studies suggest a temporary reduction in height gain of approximately 1–2 cm during the first 1–3 years of treatment, though most evidence suggests that final adult height is not significantly affected. Growth (height and weight) should be monitored at least every 6 months, and treatment interruptions (such as drug holidays during school vacations) may be considered to allow catch-up growth and to assess whether continued medication is necessary.
Seizure risk: Methylphenidate may lower the seizure threshold. It should be used with caution in patients with a history of seizures or an abnormal EEG. If seizure frequency increases, methylphenidate should be discontinued.
Abuse and dependence potential: Methylphenidate is a Schedule II controlled substance in the United States and is subject to similar controls in many other countries. It has recognized abuse potential, particularly when taken in higher-than-prescribed doses, by non-oral routes (insufflation, injection), or by individuals without ADHD. However, when used as prescribed for the treatment of ADHD, the risk of addiction is considered low. Several large population-based studies have demonstrated that individuals with ADHD who receive stimulant treatment are at lower risk of developing substance use disorders compared to untreated individuals.
Pregnancy and Breastfeeding
Methylphenidate Humantis should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. There are limited data from the use of methylphenidate in pregnant women. Animal studies have shown reproductive toxicity at supratherapeutic doses, including decreased fetal weight and skeletal variations. Some epidemiological studies have not found an increased overall risk of congenital malformations with methylphenidate use during pregnancy, but a small increase in the risk of cardiac malformations has been reported in some (but not all) studies. If a patient becomes pregnant while taking methylphenidate, the prescriber should reassess the need for treatment, weighing the risks of untreated ADHD against the potential risks of medication exposure.
Methylphenidate is excreted in human breast milk, though the amounts transferred to the nursing infant are small (estimated infant dose <0.2% of the maternal weight-adjusted dose). The clinical significance of this exposure is uncertain. The decision to continue or discontinue breastfeeding during methylphenidate treatment should be made in consultation with a healthcare provider, considering both the benefits of breastfeeding for the infant and the benefits of treatment for the mother.
Never take Methylphenidate Humantis together with an MAO inhibitor or within 14 days of stopping an MAO inhibitor. This combination can cause a dangerous and potentially life-threatening increase in blood pressure (hypertensive crisis). Tell your doctor about all medications you are currently taking before starting methylphenidate.
How Does Methylphenidate Humantis Interact with Other Drugs?
Although methylphenidate is not extensively metabolized by cytochrome P450 (CYP) enzymes – its primary metabolic pathway involves hydrolysis by the carboxylesterase enzyme CES1A1 to the inactive metabolite ritalinic acid – it can still interact with a number of medications through pharmacodynamic mechanisms. Understanding these interactions is important for safe prescribing and for patients taking multiple medications.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustment, close monitoring, or avoidance of the combination:
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| MAO Inhibitors (phenelzine, tranylcypromine, selegiline, rasagiline) | Risk of hypertensive crisis due to enhanced catecholamine effects | Contraindicated. Allow at least 14 days washout after stopping an MAOI before starting methylphenidate |
| Coumarin anticoagulants (warfarin, acenocoumarol) | Methylphenidate may inhibit the metabolism of coumarin anticoagulants, increasing their plasma concentration and anticoagulant effect | Monitor INR closely when starting, stopping, or adjusting methylphenidate dose. Adjust anticoagulant dose as needed |
| Anticonvulsants (phenytoin, phenobarbital, primidone) | Methylphenidate may inhibit the metabolism of certain anticonvulsants, increasing their serum levels and risk of toxicity | Monitor anticonvulsant serum levels and adjust doses accordingly. Watch for signs of toxicity (ataxia, nystagmus, sedation) |
| Antihypertensive agents (all classes) | Methylphenidate may reduce the effectiveness of antihypertensive medications due to its sympathomimetic blood pressure-raising effects | Monitor blood pressure regularly. Antihypertensive dose may need to be increased |
| Halogenated anesthetics (halothane, isoflurane, sevoflurane) | Risk of sudden blood pressure increase during surgery | Discontinue methylphenidate on the day of planned surgery involving halogenated anesthetics |
Minor Interactions
The following interactions are of lesser clinical significance but should still be considered:
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Tricyclic antidepressants (amitriptyline, nortriptyline, imipramine) | Methylphenidate may increase plasma levels of tricyclic antidepressants by inhibiting their metabolism | Monitor for increased TCA side effects. Dose reduction of TCA may be needed |
| SSRIs (fluoxetine, sertraline, paroxetine) | Potential for serotonergic effects when combined, though clinically significant serotonin syndrome is rare | Generally safe to combine; monitor for unusual symptoms. Widely used combination in clinical practice |
| Dopaminergic agents (levodopa, dopamine agonists) | Additive dopaminergic stimulation | Use with caution. Monitor for dyskinesias and psychiatric side effects |
| Alpha-2 agonists (clonidine, guanfacine) | Combination is sometimes used therapeutically for ADHD; rare cases of serious adverse events reported upon sudden discontinuation of clonidine | If used together, do not abruptly discontinue clonidine. Taper gradually |
| Alcohol | Alcohol may exacerbate CNS side effects of methylphenidate and may alter the release profile of modified-release formulations | Avoid alcohol consumption during treatment |
It is important to inform your doctor and pharmacist about all medications you are currently taking, including prescription drugs, over-the-counter medicines, herbal supplements, and dietary supplements. While methylphenidate has fewer CYP-mediated drug interactions than many other psychotropic medications, its pharmacodynamic interactions with other sympathomimetic, dopaminergic, and serotonergic agents must be carefully considered. Additionally, certain substances may affect the absorption of the modified-release formulation, so always follow your doctor's instructions regarding food and drink during treatment.
What Is the Correct Dosage of Methylphenidate Humantis?
The dosage of Methylphenidate Humantis must be individually adjusted according to the patient's needs and response. Treatment should be initiated at the lowest possible dose and titrated upward gradually. The goal is to find the minimum effective dose that provides optimal symptom control with the fewest side effects. Your doctor will guide you through this titration process, which typically involves weekly dose adjustments until the best balance is achieved.
Adults
Adult Dosing (18 years and older)
For adults who are methylphenidate-naive (not previously treated with methylphenidate), the recommended starting dose is 5 mg once or twice daily, with gradual titration. For patients switching from immediate-release methylphenidate, the same total daily dose can be converted to the modified-release formulation taken once daily in the morning. The maximum recommended dose is 80 mg per day, though most adults respond to doses between 20–60 mg per day. The capsule should be taken in the morning, swallowed whole with water. Your doctor should periodically evaluate whether continued treatment is necessary, ideally at least once a year.
Children (6 years and older) and Adolescents
Pediatric Dosing (6–17 years)
Treatment usually begins with 5 mg once or twice daily (when using immediate-release forms) and is converted to the appropriate modified-release dose once the optimal daily amount has been determined. The modified-release capsule is taken once daily in the morning. Dose increases should be made in increments of 5–10 mg per week. The maximum recommended daily dose is 60 mg. Clinical guidelines recommend treatment holidays (e.g., during school vacations) to assess whether the child still requires medication and to allow catch-up growth. Growth should be monitored at least every 6 months.
Elderly
Elderly Patients (65 years and older)
Methylphenidate has not been systematically studied in patients over 65 years of age. The safety and efficacy of methylphenidate in this population have not been established. If treatment is considered clinically necessary in older adults, particular caution is warranted regarding cardiovascular effects, and treatment should begin at the lowest available dose with very careful titration. Comprehensive cardiovascular assessment is recommended before initiating treatment in this age group.
Missed Dose
If you forget to take your Methylphenidate Humantis capsule in the morning, you may take it as soon as you remember, provided it is still early enough in the day that the medication will not interfere with sleep. As a general rule, if it is past midday (noon), it is usually better to skip the missed dose entirely and resume your normal dosing schedule the following morning. Do not take a double dose to compensate for a missed one. The modified-release formulation is designed for once-daily administration; taking it too late in the day can cause significant difficulty falling asleep.
Overdose
Methylphenidate overdose requires immediate medical attention. Signs and symptoms of overdose may include vomiting, agitation, tremors, muscle twitching (myoclonus), seizures, confusion, hallucinations, sweating, flushing, headache, rapid or irregular heartbeat (tachycardia, arrhythmias), high blood pressure, dilated pupils (mydriasis), and dry mucous membranes. Severe overdose may lead to hyperthermia, rhabdomyolysis, disseminated intravascular coagulation, metabolic acidosis, coma, and circulatory collapse. There is no specific antidote; treatment is supportive and symptomatic. If you suspect an overdose, call your local poison control center or emergency services immediately.
| Patient Group | Starting Dose | Titration | Maximum Daily Dose |
|---|---|---|---|
| Children (6–12 years) | 5 mg once daily | Increase by 5–10 mg weekly | 60 mg |
| Adolescents (13–17 years) | 5–10 mg once daily | Increase by 5–10 mg weekly | 60 mg |
| Adults (18–64 years) | 5 mg once or twice daily | Increase by 10–20 mg weekly | 80 mg |
| Elderly (65+ years) | Not established | With extreme caution | Not established |
What Are the Side Effects of Methylphenidate Humantis?
Like all medicines, Methylphenidate Humantis can cause side effects, although not everybody gets them. Most side effects are mild to moderate, dose-dependent, and often improve over the first few weeks of treatment or with dose adjustment. The following side effects have been reported in clinical trials and post-marketing surveillance of methylphenidate products. The frequencies below are based on pooled data from controlled clinical trials and regulatory safety databases.
Side effects are classified by frequency according to the following convention: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (<1/1,000), and Not known (cannot be estimated from available data).
Very Common
Affects more than 1 in 10 people
- Decreased appetite (the most frequently reported side effect; typically most prominent during the first few months of treatment)
- Insomnia and difficulty falling asleep (related to the stimulant mechanism; taking the medication earlier in the day may help)
- Headache
- Nervousness and restlessness
Common
Affects 1 to 10 in 100 people
- Nausea, abdominal pain, vomiting, dry mouth
- Increased heart rate (tachycardia) and palpitations
- Increased blood pressure
- Dizziness
- Mood changes including irritability, agitation, and emotional lability
- Weight loss (due to appetite suppression)
- Upper respiratory tract infection, nasopharyngitis
- Cough
Uncommon
Affects 1 to 10 in 1,000 people
- Depression, anxiety, and depressed mood
- Tics or worsening of pre-existing tic disorders
- Tremor
- Blurred vision
- Chest pain and discomfort
- Dyspnea (shortness of breath)
- Rash, pruritus (itching), urticaria (hives)
- Alopecia (hair loss)
- Muscle cramps and joint pain
- Elevated liver enzymes
Rare
Affects fewer than 1 in 1,000 people
- Psychotic symptoms (hallucinations, delusions, paranoia)
- Manic episodes
- Suicidal ideation
- Seizures
- Angina pectoris
- Cardiac arrhythmias
- Raynaud's phenomenon (reduced blood flow to fingers/toes)
- Priapism (prolonged painful erection)
- Anemia, leukopenia, thrombocytopenia
Not Known
Frequency cannot be estimated from available data
- Sudden cardiac death (extremely rare; mostly in patients with pre-existing structural cardiac abnormalities)
- Cerebrovascular events (stroke, cerebral vasculitis)
- Neuroleptic malignant syndrome (NMS)
- Serotonin syndrome (when combined with serotonergic drugs)
- Pancytopenia
- Hepatic dysfunction
- Exfoliative dermatitis and erythema multiforme
- Growth suppression with prolonged use in children
- Drug dependence (when misused)
If you experience any of the serious side effects listed above, particularly chest pain, irregular heartbeat, shortness of breath, hallucinations, unexplained skin rash, or thoughts of self-harm, contact your doctor or seek medical attention immediately. For milder side effects such as appetite reduction or difficulty sleeping, your doctor may adjust the dose or timing of your medication. Many common side effects tend to diminish after the first few weeks of treatment as your body adjusts to the medication.
Long-term treatment with methylphenidate may cause a temporary reduction in growth velocity in children. Height and weight should be carefully monitored at least every 6 months. Your doctor may recommend treatment breaks (drug holidays) during school vacations to allow catch-up growth and to assess whether continued medication is needed. If a child is not growing or gaining weight as expected, your doctor may consider temporarily stopping treatment.
How Should You Store Methylphenidate Humantis?
Proper storage of Methylphenidate Humantis is important to ensure the medication remains effective and safe throughout its shelf life. The modified-release capsule formulation is designed with specific coatings and bead technologies that can be affected by improper storage conditions, particularly excessive heat and moisture. Follow these storage guidelines carefully.
Temperature: Store at or below 30°C (86°F). Do not expose to excessive heat. Avoid leaving the medication in a car, near a window, or in other locations where temperatures may exceed this limit. Do not freeze.
Moisture protection: Store in the original packaging to protect from moisture. The blister packaging or bottle closure provides a moisture barrier that helps preserve the integrity of the modified-release coating. Do not transfer capsules to a different container unless specifically instructed by your pharmacist.
Light: While the capsule formulation provides some protection against light, it is best to store the medication in its original carton until ready to use.
Security: As a controlled substance, methylphenidate should be stored in a secure location to prevent unauthorized access, theft, or accidental ingestion by children or others for whom the medication is not prescribed. Consider using a locked medicine cabinet or other secure storage solution, particularly in households with multiple occupants.
Expiry: Do not use Methylphenidate Humantis after the expiry date printed on the packaging. The expiry date refers to the last day of that month. Expired medication should not be thrown in household waste. Ask your pharmacist how to dispose of unused or expired medication. In many countries, pharmacies accept returned medications for safe disposal.
What Does Methylphenidate Humantis Contain?
Each Methylphenidate Humantis 5 mg modified-release hard capsule contains 5 mg of methylphenidate hydrochloride as the active substance. Methylphenidate hydrochloride is a white, odorless crystalline powder that is freely soluble in water and methanol. Its molecular formula is C14H19NO2·HCl, and it has a molecular weight of 269.77 g/mol.
The modified-release capsule contains two types of beads: immediate-release beads that dissolve rapidly after ingestion, and extended-release beads coated with a pH-dependent or time-dependent polymer that delays dissolution. This dual-bead technology produces the characteristic biphasic plasma concentration profile that provides both rapid onset and sustained duration of action.
Typical excipients in the capsule contents may include:
- Sugar spheres: (sucrose and starch) serve as the core substrate upon which the drug is layered
- Povidone: acts as a binder to help the drug layer adhere to the sugar spheres
- Hypromellose (HPMC): used as a film-forming agent in the extended-release coating
- Ethylcellulose: forms part of the extended-release coating matrix
- Methacrylic acid copolymers: pH-sensitive polymers used in extended-release coatings
- Talc: anti-tacking agent in the coating
- Triethyl citrate: plasticizer for the film coating
Capsule shell: The hard capsule shell is typically composed of gelatin or hypromellose (HPMC), with colorants such as titanium dioxide (E171) and possibly iron oxides for color differentiation of different strengths. The exact composition of the capsule shell may vary by manufacturer and market.
If you have known allergies to any of the above excipients, particularly gelatin or specific colorants, inform your doctor or pharmacist before taking this medication. Patients with rare hereditary problems of fructose intolerance should note that sugar spheres contain sucrose.
Frequently Asked Questions About Methylphenidate Humantis
Methylphenidate Humantis is a prescription medication used to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents, and adults. It contains the active substance methylphenidate hydrochloride in a modified-release capsule formulation that provides sustained symptom control throughout the day. It is used as part of a comprehensive treatment program that may also include psychological, educational, and social measures. Methylphenidate helps improve focus, attention, and impulse control by increasing dopamine and norepinephrine levels in the brain.
The modified-release capsule contains two types of beads: immediate-release beads that provide a quick onset of action (within 30–60 minutes), and extended-release beads that gradually dissolve over several hours. This creates a biphasic release profile that mimics taking two separate doses of immediate-release methylphenidate – an early morning dose and a midday dose – all in a single capsule. This means you only need to take one dose in the morning for symptom coverage lasting approximately 8–12 hours, eliminating the need for a second dose during school or work hours.
Yes, for patients who have difficulty swallowing capsules, the capsule can be carefully opened and the contents sprinkled on a small amount of soft food such as applesauce, yogurt, or jam. The beads should be swallowed immediately without chewing – chewing the beads would destroy the modified-release mechanism and release the entire dose at once, potentially causing increased side effects. After sprinkling, do not save the food/bead mixture for later use; it should be consumed immediately. Always consult your doctor or pharmacist for specific instructions.
Methylphenidate has been used clinically for over 60 years and has an extensive safety record. Long-term studies in both children and adults have generally demonstrated a favorable risk-benefit profile when used as prescribed. However, long-term treatment requires regular monitoring, including assessments of cardiovascular status (blood pressure, heart rate), growth parameters (height and weight in children), and psychiatric symptoms. Your doctor should periodically evaluate whether continued treatment is necessary, typically at least once a year, and may recommend drug holidays to assess symptom control without medication. Most international guidelines support continued use as long as the benefits outweigh the risks for the individual patient.
Methylphenidate does not typically cause physical withdrawal symptoms when stopped abruptly, unlike many other controlled substances. However, ADHD symptoms will return when the medication wears off, and some people may experience a temporary period of fatigue, increased appetite, or depressed mood after discontinuation – sometimes called a “rebound” effect. If your doctor decides to stop treatment, they may recommend a gradual dose reduction rather than abrupt cessation, especially if you have been taking higher doses. Never stop or change your medication without consulting your doctor first.
Methylphenidate Humantis can be taken with or without food. Taking it with breakfast may help reduce stomach upset, which some patients experience, particularly when starting treatment. A high-fat meal may slightly delay the absorption of the immediate-release component but does not significantly affect the overall bioavailability of the drug. The most important factor is consistency – try to take it at the same time each morning to maintain steady symptom control throughout the day. Avoid taking it in the afternoon or evening, as this may cause difficulty sleeping.
References
- European Medicines Agency (EMA). Methylphenidate – Summary of Product Characteristics. Accessed 2026.
- National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management (NG87). Updated 2024.
- American Psychiatric Association (APA). Practice Guidelines for the Treatment of ADHD. Updated 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738.
- Storebø OJ, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev. 2018;5(5):CD012069.
- Faraone SV, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789–818.
- Chang Z, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014;55(8):878–885.
- European Network for Hyperkinetic Disorders (EUNETHYDIS). Guidelines on ADHD pharmacotherapy. Updated 2023.
- British National Formulary (BNF). Methylphenidate hydrochloride monograph. Accessed 2026.
Editorial Team
Medical Content
Written by iMedic Medical Editorial Team – specialists in psychiatry and clinical pharmacology
Medical Review
Reviewed by iMedic Medical Review Board according to EMA, FDA, NICE, and APA guidelines
Evidence Standard
Level 1A – Based on systematic reviews, meta-analyses of RCTs, and international clinical guidelines
Independence
No pharmaceutical funding. Independent editorial content with no commercial influence
All medical content on iMedic is developed according to strict editorial standards, reviewed by qualified medical professionals, and regularly updated to reflect the latest evidence. For more information about our editorial process, visit our Editorial Standards page.